Gyre Therapeutics, Inc. Price & Performance (GYRE)

Corteva Inc has spearheaded a major investment in Puna Bio, an Argentina-based firm focused on biological solutions for regenerative farming. This funding will help Puna Bio expand into the U.S., Brazil, and Paraguay, while supporting product development aimed at improving crop yields with environmentally friendly technologies.12

Newly published results from the CATALYST trial show that 24% of patients with difficult-to-control type 2 diabetes also have hypercortisolism. These findings highlight the need for clinicians to screen for this underlying condition, potentially improving outcomes for patients who do not respond to standard diabetes therapies.34

Novocure has received CE Mark approval for its Optune Lua device to treat metastatic lung cancer, while Vivasure Medical secured approval for its PerQseal Elite vascular closure system. Both companies plan to launch their products in select European markets this summer, signaling significant progress in the medical device sector.5